As the life expectancy of CF patients continues to increase, the number of patients seeking treatment for CF-related chronic sinus disease will most likely continue to increase.[49] In the future, studies should measure sinonasal outcome parameters, like sinus CT opacification, nNO levels and sinonasal questionnaires to gain a better understanding of the role of CFTR modulators in the treatment and follow-up of sinonasal pathology in patients with CF. Here, CFTR is linked to cystic fibrosis.